Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Price Target Raised at Wedbush

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its target price increased by research analysts at Wedbush from $99.00 to $102.00 in a research report issued on Wednesday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Wedbush‘s price objective would indicate a potential upside of 14.79% from the stock’s previous close.

A number of other analysts have also recently weighed in on KNSA. Zacks Research cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 30th. JPMorgan Chase & Co. boosted their target price on shares of Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Citigroup upped their target price on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. The Goldman Sachs Group raised their price target on shares of Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Finally, Canaccord Genuity Group raised their price target on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Eight analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Kiniksa Pharmaceuticals International has a consensus rating of “Moderate Buy” and a consensus price target of $96.86.

Kiniksa Pharmaceuticals International Price Performance

KNSA traded down $0.34 during trading on Wednesday, reaching $88.86. 135,386 shares of the company were exchanged, compared to its average volume of 688,632. The firm has a 50 day moving average of $78.23 and a 200 day moving average of $59.23. Kiniksa Pharmaceuticals International has a 52 week low of $36.56 and a 52 week high of $90.80.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. The company had revenue of $285.97 million during the quarter, compared to the consensus estimate of $260.66 million. On average, research analysts forecast that Kiniksa Pharmaceuticals International will post 1.37 earnings per share for the current year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In related news, CAO Michael Megna sold 4,600 shares of the business’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $80.30, for a total transaction of $369,380.00. Following the sale, the chief accounting officer owned 29,062 shares of the company’s stock, valued at $2,333,678.60. The trade was a 13.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 51.98% of the company’s stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Fonville Wealth Management LLC bought a new stake in Kiniksa Pharmaceuticals International in the third quarter worth about $1,478,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Kiniksa Pharmaceuticals International by 19.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,811 shares of the company’s stock valued at $667,000 after purchasing an additional 1,442 shares in the last quarter. Park Avenue Securities LLC boosted its position in shares of Kiniksa Pharmaceuticals International by 7.4% during the 3rd quarter. Park Avenue Securities LLC now owns 15,829 shares of the company’s stock valued at $1,181,000 after purchasing an additional 1,095 shares in the last quarter. Sowell Financial Services LLC bought a new position in shares of Kiniksa Pharmaceuticals International during the 3rd quarter valued at about $3,039,000. Finally, Sterling Capital Management LLC boosted its holdings in Kiniksa Pharmaceuticals International by 911.4% during the third quarter. Sterling Capital Management LLC now owns 1,507 shares of the company’s stock worth $112,000 after buying an additional 1,358 shares in the last quarter. 53.95% of the stock is owned by institutional investors.

Kiniksa Pharmaceuticals International News Roundup

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Strong earnings and revenue beat: Kiniksa reported third-quarter adjusted earnings of $0.56 per share, above the $0.32-$0.37 analyst estimates and up from $0.23 a year earlier. Revenue reached $285.97 million, exceeding the $260.66 million consensus estimate. Kiniksa Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Higher revenue outlook: Management raised expected 2026 ARCALYST net product revenue to $1.045 billion-$1.050 billion, or more than $1.045 billion, signaling continued confidence in demand for the recurrent pericarditis treatment. Kiniksa Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Rapid ARCALYST growth: Third-quarter ARCALYST revenue rose approximately 58% year over year to $286 million, while penetration among patients with multiple recurrences reached 23%, supporting the company’s commercial growth story. Kiniksa Three Key Takeaways
• Positive Sentiment: Analyst price-target increase: Wells Fargo raised its target from $87 to $110 and maintained an “overweight” rating, implying roughly 24% upside from the referenced $88.62 price. Wells Fargo Raises Kiniksa Price Target
• Positive Sentiment: Pipeline progress: KPL-387 pivotal Phase 3 data are expected in the second half of 2027, providing a potential longer-term catalyst beyond ARCALYST.
• Neutral Sentiment: Reported short interest was listed at zero shares as of October 26, offering no measurable short-position signal, although the figure may reflect a reporting anomaly.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.